Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
European Heart Journal|July 30, 2011
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes TrialPeter S Sever, Neil R Poulter, Choon L Chang, et al.
Lancet (London, England)|March 16, 2010
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertensionPeter M Rothwell, Sally C Howard, Eamon Dolan, et al.
The Lancet. Oncology|December 3, 2010
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trialsSripal Bangalore, Sunil Kumar, Sverre E Kjeldsen, et al.
American Journal of Hypertension|August 21, 2010
Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT TrialAjay K Gupta, Neil R Poulter, Joanna Dobson, et al.
American Heart Journal|February 28, 2016
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialMarc S Sabatine, Robert P Giugliano, Anthony Keech, et al.
Frontiers in Cardiovascular Medicine|April 24, 2026
A sham-controlled randomised trial evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous vagal sensory stimulation in uncontrolled hypertensive patients: rationale and study design of the SCRATCH-HTN studyAjay Gupta, David Collier, James Steckelmacher, et al.
Journal of Hypertension|March 14, 2025
Blood pressure variability: a reviewSpoorthy Kulkarni, Gianfranco Parati, Sripal Bangalore, et al.
Journal of the American College of Cardiology|April 24, 2010
Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudyRobyn J Tapp, Andrew Sharp, Alice V Stanton, et al.
JAMA Cardiology|August 24, 2017
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular DiseaseGregg C Fonarow, Anthony C Keech, Terje R Pedersen, et al.
International Journal of Cardiology|October 4, 2012
First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot studyJustin E Davies, Charlotte H Manisty, Ricardo Petraco, et al.
Pageof 9